The latest from Faes Farma

Economic and Financial News

November 4th, 2025

Faes Farma increases its revenue by more than 15% to €454 million


The company exceeds its revenue forecasts for the year as a whole thanks to the strong performance across all business areas The Pharma division posts double-digit growth (+13%) driven by strong performance […]



More info
Economic and Financial News

September 2nd, 2025

Faes Farma completes the acquisition of SIFI and consolidates its international leadership in ophthalmology


The transaction reinforces the Group’s new global strategy and boosts ophthalmology as one of its key growth areas. Thanks to this transaction and the acquisition of Edol in March, ophthalmology will account […]



More info
Economic and Financial News

July 24th, 2025

Faes Farma increases revenue by 12.3% to €307.4 million


The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The three strategic molecules (Bilastine, Calcifediol and Mesalazine) […]



More info

All the news

Economic and Financial News
July 16th, 2025

Faes Farma’s Shareholders’ Meeting approves the acquisition of 100% of SIFI

Shareholder support consolidates the transaction as a transformational step for the company’s strategy The acquisition consolidates Faes Farma as a leading ophthalmology company with one of the most comprehensive offerings in the […]

Economic and Financial News
June 25th, 2025

Faes Farma reaffirms its ambition and strategic plan to 2030 to its shareholders

The Meeting approves the payment of a final dividend of 0.138 euros per share on July 7, for a total dividend of 0.179 euros per share, a pay-out of 51%. All items […]

Economic and Financial News
June 10th, 2025

Faes Farma Acquires SIFI: A Transformational Step Aligned With 2030 Ambitions and Strategy

This acquisition consolidates Faes Farma as a leader in ophthalmology, incorporating a broad portfolio in this key therapeutic area. It enhances the Group’s international expansion, facilitating direct entry into new European markets. […]

Economic and Financial News
March 25th, 2025

Faes Farma signs an agreement to acquire Laboratorios Edol, a leader in ophthalmology in Portugal

Ophthalmology represents a key strategic opportunity for Faes Farma as it is a therapeutic area with expected double-digit growth. This milestone reinforces Faes Farma’s international growth strategy and consolidates its position in […]